{"id":"dapagliflozin-lobeglitazone","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Genital mycotic infections"},{"rate":"3-8","effect":"Urinary tract infections"},{"rate":"5-15","effect":"Polyuria"},{"rate":"2-5","effect":"Weight gain"},{"rate":"3-7","effect":"Fluid retention/edema"},{"rate":"1-3","effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL429910","moleculeType":"Small molecule","molecularWeight":"408.88"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dapagliflozin is an SGLT2 inhibitor that promotes urinary glucose excretion independent of insulin secretion. Lobeglitazone is a thiazolidinedione that enhances insulin sensitivity by activating PPAR-γ in adipose tissue and muscle. Together, they provide complementary mechanisms for glycemic control in type 2 diabetes.","oneSentence":"This combination reduces blood glucose by inhibiting sodium-glucose cotransporter 2 (SGLT2) in the kidneys while simultaneously activating peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:31:59.798Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07108985","phase":"PHASE4","title":"Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2025-09","conditions":"Diabetes Mellitus, Type 2, Hyperglycemia, Insulin Resistance","enrollment":100},{"nctId":"NCT05915949","phase":"PHASE4","title":"Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2022-01-01","conditions":"Diabetes Type 2","enrollment":99},{"nctId":"NCT02338921","phase":"PHASE4","title":"Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-01","conditions":"Type 2 Diabetes","enrollment":78}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Forxiga 10mg + Duvie 0.5mg"],"phase":"marketed","status":"active","brandName":"Dapagliflozin + Lobeglitazone","genericName":"Dapagliflozin + Lobeglitazone","companyName":"Seoul National University Bundang Hospital","companyId":"seoul-national-university-bundang-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces blood glucose by inhibiting sodium-glucose cotransporter 2 (SGLT2) in the kidneys while simultaneously activating peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}